Lantheus Holdings’ analyst price target has been reduced from approximately $86.64 to $84.29, as analysts cite concerns over Pylarify’s market share, slower uptake of Alzheimer's therapeutics, and uncertainty regarding future growth drivers.

Analyst Commentary

Recent research reports on Lantheus Holdings indicate a shift in sentiment among analysts, with revised price targets reflecting both optimism and caution. Views are largely shaped by the performance of Pylarify, ongoing competition, and visibility into future growth drivers.

Bullish Takeaways

• Bullish analysts note modest year-over-year domestic volume growth for Pylarify, despite increased competition. This indicates underlying demand resilience.
• Some remain optimistic about Lantheus' royalty opportunities from other pipeline assets, such as Flyrcado. These could offer new growth avenues.
• There is an expectation that the approval of next-generation Pylarify formulations and future pass-through statuses could support price recovery and improved earnings in 2027 and beyond.

Bearish Takeaways

• Bearish analysts emphasize near-term risks tied to Pylarify’s declining market share. They have concerns that competitive products could surpass it before key regulatory milestones are reached.
• Recent guidance cuts and lower pricing assumptions for Pylarify have led to reduced earnings projections for 2025 and 2026.
• There is heightened skepticism regarding the predictability of long-term growth drivers due to bolt-on acquisitions and slower uptake of new therapeutics. This increases uncertainty around organic growth.
• Stock performance has significantly underperformed year-to-date. Analysts are awaiting more clarity before anticipating a sustained share recovery.

What's in the News

• Lantheus and GE HealthCare have entered an exclusive licensing agreement granting GE HealthCare rights to develop and commercialize piflufolastat F18 (PYLARIFY) in Japan for prostate cancer diagnostics, including technology and regulatory dossier transfers, milestones, and royalties. (Key Developments)
• A class action lawsuit has been filed against Lantheus Holdings and certain top executives, alleging misleading statements about Pylarify’s projected outlook and underestimating competitive risks, resulting in significant stock declines after reported sales shortfalls in 2025. (Key Developments)
• The FDA has accepted a New Drug Application for a new formulation of Lantheus’ PSMA imaging agent, with an action date set for March 2026. The new formulation is expected to expand manufacturing capacity by 50% and improve patient access. (Key Developments)
• Lantheus completed the repurchase of over 2.3 million shares for nearly $200 million as part of an ongoing share buyback program. Further authorizations are in place through 2027. (Key Developments)
• Lantheus has lowered its 2025 revenue guidance to $1.475 to $1.51 billion, down from its previous outlook. (Key Developments)

Valuation Changes

• Consensus Analyst Price Target has decreased modestly from $86.64 to $84.29, reflecting reduced market optimism.
• Discount Rate has edged down slightly from 7.76% to 7.75%, indicating a minor adjustment in risk assessment.
• Revenue Growth is projected to decline marginally from 5.71% to 5.67%.
• Net Profit Margin is expected to improve incrementally from 23.03% to 23.14%.
• Future P/E has decreased from 16.51x to 16.00x, suggesting a lower valuation based on forward earnings expectations.